ArticleJournal of inflammation research2025
Characterizing Duodenal Immune Microenvironment in Functional Dyspepsia: An AutoML-Driven Diagnostic Framework.
Article in Journal of inflammation research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Transcutaneous auricular vagus nerve stimulation targets the brain-gut axis to treat functional dyspepsia: a scoping review of clinical evidence and mechanistic research.Frontiers in neuroscience · 2026Pooled it
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Functional dyspepsia (FD) is a prevalent gastroduodenal disorder with an unclear pathogenesis. Recent studies suggest that duodenal immune activation plays a pivotal role in its development. Methods: Mendelian randomization analysis using genome-wide association studies (GWAS) and expression quantitative trait loci (eQTL) data identified genes associated with FD. Expression data from 40 FD patients and 24 healthy controls were analyzed for differentially expressed genes (DEGs) using the Gene Expression Omnibus (GEO) database. Immune infiltration was assessed using CIBERSORT and xCell algorithms, followed by weighted gene co-expression network analysis (WGCNA) to identify immune-related gene modules. The top 20 critical genes were selected using maximal clique centrality (MCC), and a diagnostic model was developed using LASSO regression and multivariate logistic regression. We utilized the AutoGluon framework to automate the construction and optimization of a model based on hub genes, generating a high-performance diagnostic model. GO/KEGG and GSEA analyses were utilized to further explore the potential biological mechanisms of hub genes. Finally, FD rat models were validated for central gene and immune cell expression. Results: GWAS identified 259 genes causally linked to FD, enriched in immune and inflammatory processes. Expression analysis showed altered immune infiltration, with increased plasma cells and decreased regulatory T cells (p < 0.05). Nine biomarkers (AMBP, CHGA, GCG, SOX9, TTR, CCK, CLU, RBP4, SST) showed excellent diagnostic performance (AUC=0.94). The AutoGluon framework identified LightGBMLarge and XGBoost models as the best for clinical application. GSEA revealed high-risk groups were linked to immune-inflammatory and cell adhesion pathways. GO/KEGG analysis associated high-risk scores with oxidative stress, immune response, and nutrient metabolism. Conclusion: This study proposes immune-related diagnostic biomarkers in FD, offering insights into FD pathogenesis and potential therapeutic targets. The automated machine learning model accurately identifies high-risk FD patients and characterizes biological changes, providing new perspectives for understanding FD.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.